Drug name - Apretude
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8410103 | VIIV HLTHCARE | (3S,11aR)-N-[2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide useful as anti-HIV agent |
Apr, 2026
(3 years from now) | |
| US10927129 | VIIV HLTHCARE | N-[(2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3] oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide having HIV integrase inhibitory activity |
Apr, 2026
(3 years from now) | |
| CN101346376A | VIIV HLTHCARE | Polycyclic Carbamoylpyridone Derivative Having Inhibitory Activity On Hiv Integrase |
Jul, 2011
(11 years ago) | |
| CN101212903B | VIIV HLTHCARE | Polycyclic Carbamoyl Pyridone Derivative Having Hiv Integrase Inhibitory Activity |
Apr, 2026
(3 years from now) | |
| CN101212903A | VIIV HLTHCARE | Polycyclic Carbamoyl Pyridone Derivative Having Hiv Integrase Inhibitory Activity |
Apr, 2026
(3 years from now) | |
| EP1852434A1 | VIIV HLTHCARE | Bicyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibiting Activity |
Feb, 2026
(3 years from now) | |
| EP1852434B1 | VIIV HLTHCARE | Bicyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibiting Activity |
Feb, 2026
(3 years from now) | |
| EP1852434A4 | VIIV HLTHCARE | Bicyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibiting Activity |
Feb, 2026
(3 years from now) | |
| EP2527007B1 | VIIV HLTHCARE | Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity |
Apr, 2026
(3 years from now) | |
| EP3372281A1 | VIIV HLTHCARE | Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity |
Apr, 2026
(3 years from now) | |
| EP3187225B1 | VIIV HLTHCARE | Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity |
Apr, 2026
(3 years from now) | |
| EP3045206A1 | VIIV HLTHCARE | Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity |
Apr, 2026
(3 years from now) | |
| EP3284520A1 | VIIV HLTHCARE | Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity |
Apr, 2026
(3 years from now) | |
| EP3284520B1 | VIIV HLTHCARE | Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity |
Apr, 2026
(3 years from now) | |
| EP3187225A1 | VIIV HLTHCARE | Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity |
Apr, 2026
(3 years from now) | |
| EP3372281B1 | VIIV HLTHCARE | Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity |
Apr, 2026
(3 years from now) | |
| EP3045206B1 | VIIV HLTHCARE | Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity |
Apr, 2026
(3 years from now) | |
| EP2527007A1 | VIIV HLTHCARE | Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity |
Apr, 2026
(3 years from now) | |
| EP1874117B8 | VIIV HLTHCARE | Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity |
Apr, 2026
(3 years from now) | |
| EP1874117A4 | VIIV HLTHCARE | Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity |
Apr, 2026
(3 years from now) | |
| EP2465580A1 | VIIV HLTHCARE | Polycyclic Carbamoylpyridone Derivatives Having Hiv Integrase Inhibitory Activity |
Apr, 2026
(3 years from now) | |
| EP1874117A1 | VIIV HLTHCARE | Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity |
Apr, 2026
(3 years from now) | |
| EP1874117B1 | VIIV HLTHCARE | Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity |
Apr, 2026
(3 years from now) | |
| EP2465580B1 | VIIV HLTHCARE | Polycyclic Carbamoylpyridone Derivatives Having Hiv Integrase Inhibitory Activity |
Apr, 2026
(3 years from now) | |
| EP1950212B1 | VIIV HLTHCARE | Polycyclic Carbamoylpyridone Derivative Having Inhibitory Activity On Hiv Integrase |
Oct, 2026
(4 years from now) | |
| EP1950212A4 | VIIV HLTHCARE | Polycyclic Carbamoylpyridone Derivative Having Inhibitory Activity On Hiv Integrase |
Oct, 2026
(4 years from now) | |
| EP1950212A1 | VIIV HLTHCARE | Polycyclic Carbamoylpyridone Derivative Having Inhibitory Activity On Hiv Integrase |
Oct, 2026
(4 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11224597 | VIIV HLTHCARE | Pharmaceutical compositions |
Sep, 2031
(8 years from now) | |
Drugs and Companies using CABOTEGRAVIR ingredient
Treatment: NA
Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| 600MG/3ML (200MG/ML) | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.